Publications by authors named "A Favale"

Background: The Montreal classification has been widely used in Crohn's disease since 2005 to categorize patients by the age of onset (A), disease location (L), behavior (B), and upper gastrointestinal tract and perianal involvement. With evolving management paradigms in Crohn's disease, we aimed to assess the performance of gastroenterologists in applying the Montreal classification.

Methods: An online survey was conducted among participants at an international educational conference on inflammatory bowel diseases.

View Article and Find Full Text PDF

The nutritional status in inflammatory bowel disease (IBD) is often impaired, and adherence to the Mediterranean diet (MedDiet) remains under-investigated. The aim of this study was to assess diet quality (DQ) and adherence to MedDiet in a cohort of Sardinian IBD patients. We conducted a case-control study in which 50 Crohn's disease (CD) and 50 ulcerative colitis (UC) patients were matched with 100 healthy controls each.

View Article and Find Full Text PDF

Inflammatory bowel disease, whose major forms are Crohn's disease and ulcerative colitis, is characterized by chronic inflammation of the gut due to the loss of tolerance toward antigens normally contained in the gut lumen. G protein-coupled receptor (GPR) 120 has gained considerable attention as a potential therapeutic target for metabolic disorders due to its implication in the production of the incretin hormone glucagon-like peptide 1 and the secretion of cholecystokinin. Recent studies have also highlighted the role of GPR120 in regulating immune system activity and inflammation.

View Article and Find Full Text PDF
Article Synopsis
  • The study compared the effectiveness of ustekinumab and vedolizumab as second-line treatments for Crohn's disease in patients who did not respond to TNF inhibitors, with outcomes assessed through clinical measures and imaging techniques.
  • Results showed no significant differences in clinical outcomes at 26 weeks, but at 52 weeks, vedolizumab performed better with higher rates of clinical remission (55.5% vs 42.5%) and steroid-free remission (51.1% vs 40.6%).
  • Both treatments had similar safety profiles, and clinical responses at 26 weeks were predictive of later steroid-free remission for both medications.
View Article and Find Full Text PDF

Background And Aims: The COVID-19 pandemic has led to a deep reorganization of hospital services including inflammatory bowel disease (IBD) units. In this situation, conversion of in-person routine follow-up visits into phone consultations might be necessary. Here we explored the feasibility of using the validated Crohn's Disease (CD) or Ulcerative Colitis (UC) Patient-Reported Outcomes Signs and Symptoms (CD- and UC-PRO/SS) to collect data about abdominal symptoms (abdominal/S) and bowel signs and symptoms (bowel/SS) remotely.

View Article and Find Full Text PDF